European Commission Authorizes Lomitapide for Young HoFH Patients

The European Commission has expanded the approval for lomitapide capsules, making the medication available for children aged five and older who suffer from Homozygous Familial Hypercholesterolaemia (HoFH). This decision addresses a significant unmet medical need for younger patients with this rare genetic condition, which can lead to severe cardiovascular issues early in life. The drug is intended for use in conjunction with dietary changes and other lipid-lowering therapies.